We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

HAEMONETICS

Haemonetics Corporation’s comprehensive portfolio of devices, information management, and consulting services offers ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Vascular Closure System Permits Same-Day Discharge

By HospiMedica International staff writers
Posted on 14 Oct 2021
Print article
Image: The Vascade MVP system places a collagen patch in ablation access sites (Photo courtesy of Haemonetics)
Image: The Vascade MVP system places a collagen patch in ablation access sites (Photo courtesy of Haemonetics)
An innovative venous vascular closure device allows same-day discharge following atrial fibrillation (AF) cardiac ablation.

The Haemonetics (Braintree, MA, USA) Vascade MVP is an integrated vascular closure system that combines a small, collapsible bi-convex low profile nitinol mesh disc and thrombogenic collagen hemostatic patches to accelerate coagulation at the access site after cardiac electrophysiology procedures. The mesh disc is first approximated to the inner wall of the vessel wall to temporarily quench bleeding; a collagen patch is then released into the tissue tract, expanding approximately 13 times, and the mesh disc is then removed.

The expanded collagen ensures the residual tissue tract is sufficiently filled following completion of the ablation procedure, and is rapidly resorbed, enabling future access procedures. The Vascade MVP system has been shown to reduce time to ambulation, reduce total post-procedure time, time to hemostasis, and time to discharge eligibility in patients undergoing catheter-based procedures utilizing 6-12F inner diameter procedural sheaths, with single- or multiple-access sites in one or both limbs.

“COVID has accelerated the need to enhance safety and efficacy to optimize the patient experience in meaningful ways,” said Chris Simon, President and CEO of Haemonetics. “Vascade MVP earning the first and only indication for same-day discharge for AF ablation patients speaks to our industry leadership and continued commitment to improving the standards of care.”

Vascular access complications are frequent, and a host of strategies have therefore been developed to decrease bleeding and access site complications. Closure devices have emerged as an alternative to traditional mechanical compression, as they can reduce total time to hemostasis, reduce patient discomfort associated with prolonged bed rest, improve early mobilization and patient satisfaction, and decrease health expenditure.

Related Links:
Haemonetics


Print article
Radcal
Clear Image Devices

Channels

Business

view channel
Image: 44th World Hospital Congress (WHC) Ends on Upbeat Note as Hospital Leaders Look to Build Resilience (Photo courtesy of IHF)

44th World Hospital Congress (WHC) Ends on Upbeat Note as Hospital Leaders Look to Build Resilience

The 44th World Hospital Congress (WHC) organized by The International Hospital Federation (IHF; Geneva, Switzerland) on 8-11 November 2021 in Barcelona, Spain came to an upbeat close. During the event,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.